TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

1d ago, source:

Morgan Stanley and TD Cowen are acting as joint book-running managers for the offering. LifeSci Capital is acting as Lead Manager, and BTIG, H.C. Wainwright & Co. and Needham & Company are each acting ...

TScan Therapeutics Announces Pricing Of Public Offering - Quick Facts

1d ago, source:

TScan Therapeutics, Inc. (TCRX) announced the pricing of an underwritten public offering of 2,472,581 shares of voting common stock ...

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

1d ago, source:

WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) ...

TScan Therapeutics, Inc. (TCRX)

16d ago, source: Yahoo Finance

April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell ...

TScan Therapeutics, Inc.: TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

1d ago, source:

Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex ...

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

10d ago, source: Nasdaq

WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR ...

HOWL Werewolf Therapeutics, Inc.

20h ago, source: Seeking Alpha

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company, through its proprietary ...

TScan Therapeutics Inc TCRX

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tscan Therapeutics Inc (TCRX)

1mon ago, source: Investing

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the ...

Tscan Therapeutics Inc (TCRX)

1mon ago, source: Investing

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the... TScan ...